Skip to main content

Advertisement

Fig. 4 | Molecular Cancer

Fig. 4

From: LINC01133 as ceRNA inhibits gastric cancer progression by sponging miR-106a-3p to regulate APC expression and the Wnt/β-catenin pathway

Fig. 4

LINC01133 inhibited GC metastasis by directly targeting miR-106a-3p. a Volcano plot of different targeted miRNAs of LINC01133 on AGS cells transfected with shLINC01133–2 compared with cells transfected with scramble sequence (NC). Red marks, > 2-fold change (log2) and P <  0.05 (−log10); Green marks, < − 2-fold change (log2) and P <  0.05 (−log10). b qRT-PCR assay further confirmed the expression levels of five upregulated candidate miRNAs in 30 paired GC cancer tissues and matched normal tissues. c, d Relative expression of miR-106a-3p in AGS and BGC-823 cells transfected with miR-106a-3p mimic or inhibitor c or cells after transfection with shLINC01133 or scramble sequence (d). e Relative expression of LINC01133 in AGS and BGC-823 cells transfected with miR-106a-3p mimic or inhibitor. f Relative luciferase activities of wild type (WT) and mutated (Mut) LINC01133 reporter plasmid in human embryonic kidney (HEK) 293FT cells co-transfected with miR-106a-3p mimic. g Correlation analysis between LINC01133 and miR-106a-3p expression in 200 GC tumor tissues. h Transwell assay following low expression of LINC01133 and/or inhibition of miR-106a-3p. Representative images (left panel) and quantifications (right panel) were shown. Error bars: mean ± SD. n.s, not significant, *P <  0.05 and **P <  0.01

Back to article page